Curis Consents First Six Patients in TakeAim CLL Study
Curis has consented the first six patients in its TakeAim CLL Phase 2 study evaluating emavusertib in combination with zanubrutinib. The company reaffirmed its guidance to dose five patients by the end of July 2026, with initial data expected in December 2026.
Key figures
- Guidance
- dosing of five CLL patients by the end of July 2026, with initial CLL data expected in December 2026
- Patients consented
- 6
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.